Nippon Shinyaku Company

Minami-rinkan, Japan

Nippon Shinyaku Company

Minami-rinkan, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Nippon Shinyaku Co. | Date: 2015-06-16

Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.


Patent
Nippon Shinyaku Co. | Date: 2017-07-12

The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.


Patent
Nippon Shinyaku Co. | Date: 2017-01-18

Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.


Patent
Nippon Shinyaku Co. | Date: 2015-03-11

Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.


Patent
Nippon Shinyaku Co. | Date: 2016-10-31

The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.


Patent
Nippon Shinyaku Co. | Date: 2017-01-10

The main purpose of the invention is to provide a novel aromatic heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include aromatic heterocyclic derivatives represented by general formula [1] and pharmaceutically acceptable salts thereof. In formula [1]: R^(1 )represents phenyl optionally substituted with one or two groups selected from the group consisting of halogens, as well as alkyls and alkoxys optionally substituted by halogens; R^(2 )represents hydrogen, an alkyl, cycloalkyl, or alkoxy optionally substituted by a halogen, or a heteroaryl optionally substituted by an alkyl; X represents CR^(3), and Y represents N or CR^(4), or X represents N, and Y represents CR^(4); and Z represents CR^(5 )or N.


Patent
Nippon Shinyaku Co. | Date: 2017-04-26

Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.


Patent
Nippon Shinyaku Co. | Date: 2016-05-11

The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.


Patent
Nippon Shinyaku Co. | Date: 2015-02-06

The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.


Patent
Nippon Shinyaku Co. | Date: 2015-10-27

The present invention provides a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. For example, the present invention provides a heterocyclic derivative of the general formula [1] or its tautomer, or a pharmaceutically acceptable salt thereof: wherein R^(1 )and R^(2 )are the same or different aromatic rings, etc., and ring A is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mPGES-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease.

Loading Nippon Shinyaku Company collaborators
Loading Nippon Shinyaku Company collaborators